Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management

References

• Taefehshokr N, Baradaran B, Baghbanzadeh A, et al. Promising approaches in cancer immunotherapy. Immunobiology. 2020;225(2):151875. DOI:https://doi.org/10.1016/j.imbio.2019.11.010
   PubMed Web of Science ®Google Scholar
• Ward Grados DF, Ahmadi H, Griffith TS, et al. Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest. 2022;51(8):2226–2251.
   PubMed Web of Science ®Google Scholar
• Uliano J, Nicolò E, Corvaja C, et al. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. Expert Rev Clin Pharmacol. 2022;15(12):1399–1413.
   PubMed Web of Science ®Google Scholar
• Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–3060.
   PubMed Web of Science ®Google Scholar
• Varanasi SK, Kaech SM, Bui JD. SnapShot: cancer immunoediting. Cell. 2022:185(21):4038.e1. DOI:10.1016/j.cell.2022.09.027
   PubMedGoogle Scholar
• Bashir B, Wilson MA. Novel immunotherapy combinations. Curr Oncol Rep. 2019;21(11):96.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Public summary of opinion on orphan designation Tremelimumab for the treatment of hepatocellular carcinoma. 2021. EMADOC-628903358-3728. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/20/2370-public-summary-opinion-orphan-designation-tremelimumab-treatment-hepatocellular-carcinoma_en.pdf
   Google Scholar
• Mortezaee K, Majidpoor J, Najafi S, et al. Bypassing anti-PD-(L)1 therapy: mechanisms and management strategies. Biomed Pharmacother. 2023;158:114150.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Santoni M, Mollica V, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17(12):1455–1466.
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023. DOI:10.1007/s00262-022-03349-4
   Web of Science ®Google Scholar
• Mollica V, Santoni M, Matrana MR, et al. Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Target Oncol. 2022;17(1):61–68.
   PubMed Web of Science ®Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574. DOI:10.1093/annonc/mdv623
   PubMed Web of Science ®Google Scholar
• Ruggiero R, Stelitano B, Fraenza F, et al. Neurological manifestations related to immune checkpoint inhibitors: reverse translational research by using the european real-world safety data. Front Oncol. 2022 [Published 2022 Mar 15];12:824511. DOI:10.3389/fonc.2022.824511
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519–527.
   PubMed Web of Science ®Google Scholar
• Feng S, Coward J, McCaffrey E, et al. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017;12(11):1626–1635.
   PubMed Web of Science ®Google Scholar
• Rosellini M, Marchetti A, Mollica V, et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2023;20(3):133–157.
   PubMed Web of Science ®Google Scholar
• Qiu H, Min Y, Rodgers Z, et al. Nanomedicine approaches to improve cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5). DOI:10.1002/wnan.1456
   Web of Science ®Google Scholar
• Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–129. DOI:10.1016/j.ejca.2017.01.035
   PubMed Web of Science ®Google Scholar
• Rojas-Domínguez A, Arroyo-Duarte R, Rincón-Vieyra F, et al. Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian. BMC Bioinf. 2022 Published 2022 May 30;23(1):200. DOI:10.1186/s12859-022-04731-w
   PubMed Web of Science ®Google Scholar
• Eskandari-Malayeri F, Rezaei M. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: a comprehensive review. Front Immunol. 2022 Published 2022 Oct 5;13:996145. DOI:10.3389/fimmu.2022.996145.
   PubMed Web of Science ®Google Scholar
• Al-Mterin MA, Alsalman A, Elkord E. Inhibitory immune checkpoint receptors and ligands as prognostic biomarkers in COVID-19 Patients. Front Immunol. 2022 Published 2022 Mar 31;13:870283. DOI:10.3389/fimmu.2022.870283
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. DOI:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Pan M, Zhao H, Jin R, et al. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. Front Immunol. 2023 Published 2023 Apr 6;14:1156212. DOI:10.3389/fimmu.2023.1156212
   PubMed Web of Science ®Google Scholar
• Kennedy A, Robinson MA, Hinze C, et al. The CTLA-4 immune checkpoint protein regulates PD-L1: pD-1 interaction via transendocytosis of its ligand CD80. Embo J. 2023;42(5):e111556.
   PubMed Web of Science ®Google Scholar
• Chen CY, Huang CH, Chen WC, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. Int Immunopharmacol. 2022:108;108848. DOI:10.1016/j.intimp.2022.108848
   PubMed Web of Science ®Google Scholar
• Zhang C, Xiang Y, Wang J, et al. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: a systematic review and network meta-analysis Front Oncol. 2021 [Published 2021 Oct 22];11:734323. DOI:10.3389/fonc.2021.734323
   Google Scholar
• Xu Q, Zhang X, Huang M, et al. Comparison of efficacy and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Front Immunol. 2021 [Published 2021 Aug 16];12:731546. DOI:10.3389/fimmu.2021.731546
   PubMed Web of Science ®Google Scholar
• Lv JW, Li JY, Luo LN, et al. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials. Immunother Cancer. 2019;7(1):159.
   PubMedGoogle Scholar
• Farooq MZ, Aqeel SB, Lingamaneni P, et al. Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open. 2022 [Published 2022 Apr 1];5(4):e227722. DOI:10.1001/jamanetworkopen.2022.7722
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580.
   PubMed Web of Science ®Google Scholar
• Myers Bscpharm Acpr G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018;25(5):342–347.
   PubMed Web of Science ®Google Scholar
• Vilariño N, Bruna J, Kalofonou F, et al. Molecular sciences immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors. Int J Mol Sci. 2020;21(16):5774.
   PubMed Web of Science ®Google Scholar
• Tiu BC, Zubiri L, Iheke J, et al. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022;10(6):e004670.
   PubMed Web of Science ®Google Scholar
• Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021;20(8):883–888.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264–266]. DOI:10.1093/annonc/mdy162
   PubMedGoogle Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792. DOI:10.1200/JCO.2015.66.1389
   PubMed Web of Science ®Google Scholar
• Yang F, Shay C, Abousaud M, et al. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res. 2023;42(1):4.
   PubMed Web of Science ®Google Scholar
• Ruggiero R, Fraenza F, Scavone C, et al. Immune checkpoint inhibitors and immune-related adverse drug reactions: data from italian pharmacovigilance database. Front Pharmacol. 2020 [Published 2020 Jun 9];11:830. DOI:10.3389/fphar.2020.00830
   PubMed Web of Science ®Google Scholar
• Mascolo A, Scavone C, Ferrajolo C, et al. Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance. Drug Saf. 2021;44(9):957–971.
   PubMed Web of Science ®Google Scholar
• Hou J, Xie R, Zhang Z, et al. Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: a systematic review and network meta-analysis of phase 3 trials. Front Pharmacol. 2023;14:1163971.
   PubMed Web of Science ®Google Scholar
• Bruna J, Argyriou AA, Anastopoulou GG, et al. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials. J Peripher Nerv Syst. 2020;25(2):171–177.
   PubMed Web of Science ®Google Scholar
• Gan L, Liu D, Ma Y, et al. Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges. Front Pharmacol. 2022;13:962596.
   PubMed Web of Science ®Google Scholar
• Ellithi M, Elnair R, Vin Chang G, et al. Toxicities of immune checkpoint inhibitors: itis-ending adverse reactions and more. Cureus. 2020;12(2):e6935. DOI:10.7759/cureus.6935
   PubMed Web of Science ®Google Scholar
• Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: eSMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–1238.
   PubMed Web of Science ®Google Scholar
• Sebbag E, Psimaras D, Baloglu S, et al. Immune-related cerebellar ataxia: a rare adverse effect of checkpoint inhibitor therapy. J Neuroimmune Pharmacol. 2022;17(3–4):377–379.
   PubMed Web of Science ®Google Scholar
• Hyun JW, Kim KH, Kim SH, et al. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea. J Cancer Res Clin Oncol. 2022. DOI:10.1007/s00432-022-04516-x
   PubMedGoogle Scholar
• Braden J, Lee JH. Immune checkpoint inhibitor induced pericarditis and encephalitis in a patient treated with ipilimumab and nivolumab for metastatic melanoma: a case report and review of the literature. Front Oncol. 2021 Published 2021 Dec 9;11:749834. DOI:10.3389/fonc.2021.749834
   PubMed Web of Science ®Google Scholar
• Marzoughi S, Chen T. Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: case series. eNeurologicalsci. 2021;25:100356.
   PubMedGoogle Scholar
• Martinot M, Ahle G, Petrosyan I, et al. Progressive multifocal leukoencephalopathy after treatment with nivolumab. Emerg Infect Dis. 2018;24(8):1594–1596. Centers for Disease Control and Prevention (CDC). DOI:10.3201/eid2408.180460
   PubMed Web of Science ®Google Scholar
• Vinatier E, Poli C, Giltat A, et al. Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: a consequence of an immune reconstitution inflammatory syndrome? EJHaem. 2022 Published 2022 May 29;3(3):958–961. DOI:10.1002/jha2.485
   PubMedGoogle Scholar
• Koralnik IJ. Can immune checkpoint inhibitors keep JC virus in check? N Engl J Med. 2019;380(17):1667–1668.
   PubMed Web of Science ®Google Scholar
• Baena-Álvarez B, Rodríguez-Jorge F, Beltrán-Corbellini Á, et al. Progressive multifocal leukoencephalopathy, advanced ductal breast carcinoma, systemic sclerosis, and checkpoint inhibitors: a therapeutic dilemma. J Neurovirol. 2023;29(1):116–119.
   PubMed Web of Science ®Google Scholar
• Lambert N, El Moussaoui M, Ritacco C, et al. Killing two birds with one stone: effective control of both non-small cell lung cancer and progressive multifocal leukoencephalopathy with atezolizumab, a case report. Front Immunol. 2022;13:889148.
   PubMed Web of Science ®Google Scholar
• Barritt AW, Das E, Morley N, et al. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis Mult Scler. 2023;29(2):301–306. DOI:10.1177/13524585221137279
   Google Scholar
• Sim BZ, Smith LK, Yarwood T, et al. Successful treatment of HIV-associated progressive multifocal leukoencephalopathy with pembrolizumab. AIDS. 2022;36(3):483–485. DOI:10.1097/QAD.0000000000003118
   PubMed Web of Science ®Google Scholar
• Rauer S, Marks R, Urbach H, et al. Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med. 2019;380(17):1676–1677.
   PubMed Web of Science ®Google Scholar
• Darcy S, Alexander M, Mccarthy A, et al. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases. J Neurovirol. 2022;28(1):145–150.
   PubMed Web of Science ®Google Scholar
• Mackenzie S, Shafat M, Roddy H, et al. Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report. EJHaem. 2021 Aug 4;2(4). PMID: 35845220; PMCID: PMC9281485. 848–853. DOI:10.1002/jha2.274
   PubMedGoogle Scholar
• Lan TY, Chen YS, Cheng CF, et al. Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: a case report with literature review. Lupus. 2021;30(11):1849–1855.
   PubMed Web of Science ®Google Scholar
• Haroche J, Aubart FC, Mokhtari K, et al. Immune reconstitution syndrome after nivolumab for progressive multifocal leukoencephalopathy. Neurol Clin Pract. 2021;11(3):e376–378.
   PubMedGoogle Scholar
• Chen G, Zhang C, Jiaying LAN, et al. Atezolizumab-associated encephalitis in metastatic breast cancer: a case report. Oncol Lett. 2022 Jul 27;24(3):324. PMID: 35949609; PMCID: PMC9353807. DOI:10.3892/ol.2022.13444
   PubMed Web of Science ®Google Scholar
• Lallana S, Sánchez-Tejerina D, Auger C, et al. Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. Acta Neurol Belg. 2022;122(3):823–825.
   PubMed Web of Science ®Google Scholar
• Bir Yucel K, Sutcuoglu O, Yazıcı O, et al. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. J Oncol Pharm Pract. 2023;29(3):760–763.
   PubMed Web of Science ®Google Scholar
• Chisaki Y, Hata H, Matsumura C, et al. The occurrence of encephalitis due to immune checkpoint inhibitors: a pharmacovigilance study. Ther Innov Regul Sci. 2022;56(2):323–332.
   PubMed Web of Science ®Google Scholar
• Müller-Jensen L, Zierold S, Versluis JM, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer. 2022;175:224–235.
   PubMedGoogle Scholar
• Lorente-Ros Á, Rajjoub-Al-Mahdi EA, Monteagudo Ruiz JM, et al. Checkpoint immunotherapy-induced myocarditis and encephalitis complicated with complete AV block: not all hope is lost. JACC Case Rep. 2022;4(16):1032–1036.
   PubMedGoogle Scholar
• Akazawa S, Otsuka Y, Hashimoto R, et al. [A case of myopathy, myocarditis, and encephalitis with nonconvulsive status epileptics after immune checkpoint inhibitor therapy for ureter cancer]. Y. Rinsho Shinkeigaku. 2022;62(5):395–398.
   PubMedGoogle Scholar
• Wölffer M, Battke F, Schulze M, et al. Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma. Cancers (Basel). 2022 Jan 8;14(2). PMID: 35053465; PMCID: PMC8773840. 302. DOI:10.3390/cancers14020302
   PubMed Web of Science ®Google Scholar
• Alvi R, Drobni Z, Zafar A, et al. Cardiovascular and cerebrovascular events among patients receiving immune checkpoint inhibitors. J Am Coll Cardiol. 2020 Mar;75(11_Supplement_1):36. DOI:10.1016/S0735-1097(20)30663-X
   Web of Science ®Google Scholar
• Watanabe R, Zhang H, Berry G, et al. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol. 2017;312(5):H1052–1059.
   PubMed Web of Science ®Google Scholar
• Läubli H, Hench J, Stanczak M, et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer. 2017 [Published 2017 Jun 20];5:46. DOI:10.1186/s40425-017-0249-y
   PubMed Web of Science ®Google Scholar
• Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37(9):2579–2584.
   PubMed Web of Science ®Google Scholar
• Kim JE, Patel K, Jackson CM. The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. Expert Opin Ther Targets. 2021;25(2):101–113.
   PubMed Web of Science ®Google Scholar
• Kawamura R, Nagata E, Mukai M, et al. Acute cerebellar ataxia induced by nivolumab. Intern Med. 2017;56(24):3357–3359.
   PubMed Web of Science ®Google Scholar
• Zurko J, Mehta A. Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):74–77.
   PubMedGoogle Scholar
• Saikawa H, Nagashima H, Maeda T, et al. Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor. BMJ Case Rep. 2019;12(12):e231520.
   PubMedGoogle Scholar
• Dinoto A, Mantovani E, Ferrari S, et al. Cerebellar involvement associated with immune checkpoint inhibitors: a systematic review. Eur J Neurol. 2023;30(3):774–781.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Manto M, Hadjivassiliou M. Immune-mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms. J Mov Disord. 2021;14(1):10–28.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Chmp. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS.
   Google Scholar
• Gu Y, Menzies AM, Long GV, et al. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017;45:14–17.
   PubMed Web of Science ®Google Scholar
• Rocha Cabrero F, Morrison EH. Miller Fisher Syndrome. In StatPearls. Treasure Island (FL):StatPearls Publishing;Sep 21, 2022. Available from https://pubmed.ncbi.nlm.nih.gov/29939539/
   Google Scholar
• Li Y, Zhang X, Zhao C. Guillain-Barré syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 Cases. BioMed Res Int. 2021 Published 2021 Aug 19;2021:9800488. DOI:10.1155/2021/9800488
   PubMed Web of Science ®Google Scholar
• Okada K, Seki M, Yaguchi H, et al. Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol. 2021;268(2):680–688.
   PubMed Web of Science ®Google Scholar
• Chen X, Haggiagi A, Tzatha E, et al. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol. 2019;130(8):1440–1445.
   PubMed Web of Science ®Google Scholar
• Schwab A, Assaad M, Hamadi R, et al. Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors. J Med Cases. 2022;13(11):530–535.
   PubMedGoogle Scholar
• De Grado A, Cencini F, Priori A. Neurology of cancer immunotherapy. Neurol Sci. 2023;44(1):137–148.
   PubMed Web of Science ®Google Scholar
• Manson G, Maria ATJ, Poizeau F, et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer. 2019;7(1):337.
   PubMed Web of Science ®Google Scholar
• Honnorat J, Antoine JC. Paraneoplastic neurological syndromes.Orphanet J Rare Dis. 2007 [Published 2007 May 4];2(1):22. DOI:10.1186/1750-1172-2-22
   PubMedGoogle Scholar
• Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16(9):535–548.
   PubMed Web of Science ®Google Scholar
• Gill AJ, Perez MA, Perrone CM, et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol. 2019;334:576980.
   PubMed Web of Science ®Google Scholar
• Raibagkar P, Ho D, Gunturu KS, et al. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: case report and review of literature. J Neuroimmunol. 2020;341:577184.
   PubMed Web of Science ®Google Scholar
• Blackmon JT, Viator TM, Conry RM. Central nervous system toxicities of anti-cancer immune checkpoint blockade. Eur J Endocrinol. 2013;169(6):R153–164.
   PubMedGoogle Scholar
• Weber JS, Postow M, Lao CD, et al. Melanoma and cutaneous malignancies management of adverse events following treatment with anti-programmed death-1 agents. Oncology. 2016;21(10):1230–1240.
   Google Scholar
• Tsuji M, Hayashi N. An exploratory cross-sectional study of immune checkpoint inhibitors and immuno-related adverse events: knowledge and influencing factors among Japanese oncology nurses. Asia Pac J Oncol Nurs. 2022;10(1):100147.
   PubMed Web of Science ®Google Scholar
• Ruggiero R, Balzano N, Di Napoli R, et al. Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19. Expert Rev Clin Pharmacol. 2022;15(10):1225–1231.
   PubMed Web of Science ®Google Scholar